Next Article in Journal
Locoregional Surgery in Metastatic Breast Cancer: Do Concomitant Metabolic Aspects Have a Role on the Management and Prognosis in this Setting?
Next Article in Special Issue
Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer
Previous Article in Journal
The Application of Deep Convolutional Neural Networks to Brain Cancer Images: A Survey
Previous Article in Special Issue
Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy
Review

Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2020, 10(4), 225; https://doi.org/10.3390/jpm10040225
Received: 28 October 2020 / Revised: 8 November 2020 / Accepted: 10 November 2020 / Published: 13 November 2020
(This article belongs to the Special Issue Personalized Medicine in Oncology)
The treatment of metastatic renal cell carcinoma has evolved quickly over the last few years from a disease managed primarily with sequential oral tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF) pathway, to now with a combination of therapies incorporating immune checkpoint blockade (ICB). Patient outcomes have improved with these innovations, however, controversy persists regarding optimal sequence and patient selection amongst the available combinations. Ideally, predictive biomarkers would aid in guiding treatment decisions and personalizing care. However, clinically-actionable biomarkers have remained elusive. We aim to review the available evidence regarding biomarkers for both TKIs and ICB and will present where the field may be headed in the years to come. View Full-Text
Keywords: biomarkers; renal cell carcinoma; clear cell; VEGF; immunotherapy; PD-L1; immune checkpoint inhibitors; immune checkpoint blockade; tyrosine-kinase inhibitors biomarkers; renal cell carcinoma; clear cell; VEGF; immunotherapy; PD-L1; immune checkpoint inhibitors; immune checkpoint blockade; tyrosine-kinase inhibitors
Show Figures

Graphical abstract

MDPI and ACS Style

Miron, B.; Xu, D.; Zibelman, M. Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond. J. Pers. Med. 2020, 10, 225. https://doi.org/10.3390/jpm10040225

AMA Style

Miron B, Xu D, Zibelman M. Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond. Journal of Personalized Medicine. 2020; 10(4):225. https://doi.org/10.3390/jpm10040225

Chicago/Turabian Style

Miron, Benjamin; Xu, David; Zibelman, Matthew. 2020. "Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond" J. Pers. Med. 10, no. 4: 225. https://doi.org/10.3390/jpm10040225

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop